# Department of Health and Social Care

Type: organization

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/department-of-health-and-social-care-organization
Canonical HTML page: https://getbiobrief.com/entity/department-of-health-and-social-care-organization

## Timeline

- **2026-04-12**: Scheduled Re-evaluation — NICE appraisal committee is set to meet for a second round of evidence review.
- **2026-03-19**: NHS Impact Probe — The inquiry sets out detailed evidence regarding the pandemic's impact on NHS patients and staff.
- **2026-03-06**: Public Campaign Launch — Bereaved family launches a national campaign imploring the NHS to reconsider the approval.
- **2026-01-15**: NICE Initial Review — NICE issues a preliminary recommendation against the drug due to cost-effectiveness concerns.
- **2025-11-10**: FDA Approval — The treatment receives accelerated approval in the United States for aggressive cancer types.
- **2024-09-09**: Module 3 Hearings Begin — Public hearings start for the module focused on the impact on healthcare systems.
- **2022-06-28**: Inquiry Established — The UK COVID-19 Inquiry is formally set up to examine the UK's response to the pandemic.
- **2020-03-23**: First National Lockdown — UK government imposes stay-at-home orders, significantly impacting NHS service delivery.

## Recent coverage (2 stories)

### UK COVID-19 Inquiry Shifts Focus to NHS Impact and Healthcare Resilience
2026-03-19 03:33:12 · Sentiment: Neutral · Impact: 6/10 · Sources: 3

The UK’s public inquiry into the COVID-19 pandemic has entered a critical phase, examining the systemic impact on the National Health Service (NHS) and patient outcomes. This module scrutinizes healthcare capacity, the management of non-COVID services, and the effectiveness of medical interventions during the crisis.
Full story: https://getbiobrief.com/story/uk-covid-inquiry-nhs-impact-analysis

### NHS Faces Mounting Pressure to Approve Breakthrough Aggressive Cancer Therapy
2026-03-06 01:23:00 · Sentiment: Negative · Impact: 7/10 · Sources: 11

A bereaved family's public campaign has reignited a national debate over the NHS's drug appraisal process for aggressive cancers. The movement highlights the growing tension between fiscal cost-effectiveness and the urgent need for life-extending therapies already available in other markets.
Full story: https://getbiobrief.com/story/nhs-cancer-treatment-approval-campaign

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.